Skip to content

Journal · Cardiotoxicology · Updated 21 November 2026

Cardiovascular Toxicology

Read Cardiovascular Toxicology articles on DeepDyve. No university library needed.

Cardiovascular Toxicology covers how drugs, metals and environmental exposures harm the heart and blood vessels, from chemotherapy and microplastics to copper- and iron-related heart damage and arsenic. Springer Nature publishes it. Cardiovascular Toxicology has published since 2001. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Cardiovascular Toxicology
Journal cover

Cardiovascular Toxicology at a glance

Full title
Cardiovascular Toxicology
Abbreviation (NLM)
Cardiovasc Toxicol
Publisher
Springer Nature
Print ISSN
1530-7905
Online ISSN (eISSN)
1559-0259
First published
2001
Subjects
Cardiology, Toxicology, Vascular Diseases
Access model
Hybrid (25% free to read in 2026)

Ways to access Cardiovascular Toxicology

25% of the articles Cardiovascular Toxicology published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 25% of Cardiovascular Toxicology articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Cardiovascular Toxicology. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Cardiovascular Toxicology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Cardiovascular Toxicology’s 2025 Journal Impact Factor is 3.3, and its 5-year Impact Factor is 3.7.

3.3

Journal Impact Factor (2025)

3.7

5-year Impact Factor (2025)

10 days

Median time to first decision

Source: journal metrics on the Cardiovascular Toxicology homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Cardiovascular Toxicology research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. LitStreamCardio-oncology · Leukemia

    Beyond Remission: The Cardiotoxic and Thrombotic Shadow of AML Chemotherapy

    The authors review heart damage and blood clots caused by acute myeloid leukemia chemotherapy, noting anthracycline myocardial injury in up to 20% of patients, and propose biomarker risk scoring, machine learning prediction and targeted drug delivery to reduce the burden.

    Heydari et al. · Cardiovascular Toxicology, published online February 24, 2026 · DOI 10.1007/s12012-026-10104-z

  2. Open accessMicroplastics · Atherosclerosis

    Microplastics and Nanoplastics in Cardiovascular Disease: An Emerging Cardiovascular Risk Factor

    The authors review evidence that micro- and nanoplastics cross into the circulation and build up in arterial plaques, thrombi and heart tissue, where they can drive oxidative stress and endothelial injury, and argue they should be treated as an emerging cardiovascular risk factor.

    Polimeni et al. · Cardiovascular Toxicology, published online April 13, 2026 · DOI 10.1007/s12012-026-10112-z

  3. LitStreamCuproptosis · Cardiovascular disease

    Cuproptosis and Its Impact on Cardiovascular Health: Mechanisms and Therapeutic Opportunities

    The authors review cuproptosis, a copper-dependent form of cell death, and how it may contribute to atherosclerosis, heart failure, atrial fibrillation and other heart conditions, and discuss copper chelators, ionophores and chaperone inhibitors as possible treatments.

    Huang et al. · Cardiovascular Toxicology, published online January 27, 2026 · DOI 10.1007/s12012-026-10094-y

  4. LitStreamIron metabolism · Heart failure

    Iron Balance and Cardiovascular Health: The Double-Edged Role of Deficiency and Overload

    The authors review how both iron deficiency, which affects over 60% of heart failure patients, and iron overload harm the heart, describing a U-shaped relationship with outcomes and benefits of intravenous iron in patients with low transferrin saturation.

    Awashra et al. · Cardiovascular Toxicology, published online January 5, 2026 · DOI 10.1007/s12012-025-10086-4

  5. LitStreamArsenic · Network pharmacology

    Integrative Network Pharmacology and Molecular Docking-Based Validation of Berberine as a Therapeutic Agent in Arsenic-Induced Cardiotoxicity

    Using network pharmacology and molecular docking, the authors report 17 targets shared by berberine and arsenic-induced cardiotoxicity, involving TNF, VEGF and AGE-RAGE signaling, with the strongest predicted binding to ABL-1 at −9.2 kcal/mol.

    Krishnamoorthy et al. · Cardiovascular Toxicology, published online January 5, 2026 · DOI 10.1007/s12012-025-10083-7

See every Cardiovascular Toxicology article on DeepDyve

Questions about Cardiovascular Toxicology

How can I read Cardiovascular Toxicology articles without a subscription?

25% of Cardiovascular Toxicology articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Cardiovascular Toxicology articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Cardiovascular Toxicology?

Cardiovascular Toxicology’s NLM (PubMed) abbreviation is Cardiovasc Toxicol.

What is the ISSN of Cardiovascular Toxicology?

The print ISSN is 1530-7905 and the online ISSN is 1559-0259.

What is the impact factor of Cardiovascular Toxicology?

Cardiovascular Toxicology’s Journal Impact Factor is 3.3 (2025), and its 5-year Impact Factor is 3.7, according to Springer Nature’s published metrics.

Is Cardiovascular Toxicology open access?

Cardiovascular Toxicology is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 34 of 135 Cardiovascular Toxicology articles (25%) carry a Creative Commons license, per Crossref.

Cardiovascular Toxicology articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Cardiovascular Toxicology today

One month free, then less than $2 a day. Cardiovascular Toxicology, plus millions of articles from thousands of journals.

Start free month

Like this: